Media

The following information is intended as a resource for journalists only and was factually correct at the time it was issued.

Lisa Maguire
Director, Communications and Patient Relations
Australia and New Zealand
+ 61 499 200 550
lisa.maguire@abbvie.com

Kate Richards
Head of Corporate Communications
Australia and New Zealand
+61 466 420 739    
kate.richards@abbvie.com

AbbVie Australia follows Medicines Australia’s Code of Conduct and the Therapeutic Goods Act.​ Both prohibit a pharmaceutical company from direct to consumer advertising which includes issuing media statements about our prescription medicines. We can issue statements to advise registration of a new medicine, a reimbursement notice of a medicine or news not related to our medicines.

2018

October

AbbVie Welcomes TGA Regulatory Approval of VENCLEXTA® (venetoclax tablets) in Combination with Rituximab
Read full media release here.

August

Eight-week Hepatitis C Treatment on Pharmaceutical Benefits scheme from 1st August 2018
Read full media release here.

April

Announcement: Venclexta PBS Status
Read full media release here.

February

Experts concerned Parksinon’s patients may be missing out on support in the Illawarra
Read full media release here.